Illumina (NASDAQ:ILMN) SVP Patricia Leckman Sells 783 Shares

Illumina, Inc. (NASDAQ:ILMN) SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Shares of Illumina stock opened at $160.03 on Wednesday. The stock has a market cap of $24.21 billion, a PE ratio of 29.10, a price-to-earnings-growth ratio of 2.96 and a beta of 1.50. The business has a fifty day simple moving average of $139.27 and a 200-day simple moving average of $134.20. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $85.00 and a 12 month high of $177.22.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Institutional Trading of Illumina

Institutional investors have recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new stake in Illumina during the fourth quarter valued at $25,000. Board of the Pension Protection Fund acquired a new stake in Illumina during the fourth quarter valued at $26,000. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Illumina during the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina during the fourth quarter valued at $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ILMN. Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Guggenheim raised their target price on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Canaccord Genuity Group decreased their target price on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research report on Friday, May 1st. Royal Bank Of Canada started coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Finally, Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $138.38.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.